What is PADCEV?
PADCEV (PAD-sev), also known as enfortumab vedotin (en-FOR-too-mab veh-DOH-tin), is a type of prescription medicine known as an antibody-drug conjugate, or ADC.
• PADCEV is different from the or you may have had before
• PADCEV is thought to work by delivering cell-killing medicine directly to cancer cells.* However, it can also affect normal cells and cause side effects
•Learn about possible side effects with PADCEV, and talk to your healthcare professional about them
*This is how PADCEV was shown to work in lab studies.
PADCEV is made of 3 parts:
An that attaches to a certain type of protein on the surface of a cell
A link that connects the cell‑killing medicine to the antibody
Cell-killing medicine that is released inside of the cell
PADCEV is thought to target certain cancer cells with cell-killing medicine
PADCEV attaches to the surface of the cancer cell.
PADCEV enters the cancer cell and releases cell-killing medicine.
The medicine works to damage and kill the cancer cell.
This is how PADCEV was shown to work in lab studies.
Learn how PADCEV alone is given in a 28-day treatment cycle.
PADCEV with pembrolizumab (Keytruda®)
Combines 2 therapies that treat advanced bladder cancer in different ways
PADCEV delivers cell-killing medicine to certain cancer cells.
Pembrolizumab helps prevent certain cancer cells from hiding and allows your immune system to find and fight them.
PADCEV and pembrolizumab each work to treat advanced bladder cancer in different ways.
Please see the pembrolizumab patient medication guide for important safety information.
Learn how PADCEV with pembrolizumab is given in a 21-day treatment cycle.
Please see full Prescribing Information/Patient Information for
more information, including risk of Serious Side Effects.